Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

Hellenic Cooperative Oncology Group

Status: Completed

Conditions: Metastatic Cancer; Breast Cancer

Treatments: Drug: Antibody-Drug Conjugates

Study type: Observational

Funder types: Other

Identifiers

NCT06504719

HE 11 ADC/23

Details and patient eligibility

About

The study aims to evaluate real-world efficacy and toxicity data of treatment with Trastuzumab deruxtecan (T-DXd), a HER2-targeting ADC and sacituzumab govitecan (SG), a TROP-2-targeting ADC in pretreated patients with advanced breast cancer.

Full description

Antibody-drug conjugates (ADCs) have significantly changed the therapeutic landscape of advanced breast cancer. Trastuzumab deruxtecan (T-DXd), a HER2-targeting ADC and sacituzumab govitecan (SG), a TROP-2-targeting ADC, recently demonstrated superior efficacy over standard of care treatments depending on breast cancer subtype. The study aims to evaluate real-world efficacy and toxicity data of treatment with T-DXd and SG in pretreated patients with advanced breast cancer.

This study includes a retrospective/prospective multicenter review of medical records of patients with advanced breast cancer who received treatment with T-DXd and SG at Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG).

Enrollment: 312 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed metastatic/recurrent breast cancer
• 18 years of age
• Triple-negative (TNBC), HER2-positive and/or hormone receptor positive advanced breast cancer
• Treatment with an ADC at any of line of treatment
• Treatment with at least one cycle of T-DXd and/or SG

Exclusion criteria

• NA

Trial design

312 participants in 1 patient group

Patients treated with trastuzumab deruxtecan or sacituzumab govitecan

Description:

Patients with TNBC, HER2-positive and/or hormone receptor positive advanced breast treated with trastuzumab deruxtecan or sacituzumab govitecan

Treatment:

Drug: Antibody-Drug Conjugates